<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta charset="utf-8" />
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="generator" content="pandoc" />
<meta name="viewport" content="width=device-width, initial-scale=1">



<title>Cost-Effectiveness of RSV Preventive Interventions in Mali</title>






<!--
Font-awesome icons ie github or twitter
-->
<link rel="stylesheet" href="https://use.fontawesome.com/releases/v5.8.1/css/all.css" integrity="sha384-50oBUHEmvpQ+1lW4y57PTFmhCaXp0ML5d60M1M7uH2+nqUivzIebhndOJK28anvf" crossorigin="anonymous">
<link rel="stylesheet" href="https://use.fontawesome.com/releases/v5.8.1/css/brands.css" integrity="sha384-n9+6/aSqa9lBidZMRCQHTHKJscPq6NW4pCQBiMmHdUCvPN8ZOg2zJJTkC7WIezWv" crossorigin="anonymous">

<!--
Google fonts api stuff
-->
<link href='https://fonts.googleapis.com/css?family=Rasa' rel='stylesheet'>
<link href='https://fonts.googleapis.com/css?family=Rasa' rel='stylesheet'>

<!--
Here are the required style attributes for css to make this poster work :)
-->
<style>
@page {
size: 46in 32in;
margin: 0;
padding: 0;
background-color: #ffffff;
}
body {
margin: 0px;
padding: 0px;
width: 46in;
height: 32in;
text-align: justify;
font-size: 45px;
background-color: #FFFFFF;
color: #000000;
}
/* RMarkdown Class Styles */
/* center align leaflet map,
from https://stackoverflow.com/questions/52112119/center-leaflet-in-a-rmarkdown-document */
.html-widget {
margin: auto;
position: sticky;
margin-top: 2cm;
margin-bottom: 2cm;
}
.leaflet.html-widget.html-widget-static-bound.leaflet-container.leaflet-touch.leaflet-fade-anim.leaflet-grab.leaflet-touch-drag.leaflet-touch-zoom {
position: sticky;
width: 100%;
}
pre.sourceCode.r {
background-color: #dddddd40;
border-radius: 4mm;
padding: 4mm;
width: 75%;
margin: auto;
margin-top: 1em;
margin-bottom: 1em;
/* align-items: center; */
}
code.sourceCode.r{
background-color: transparent;
font-size: 20pt;
border-radius: 2mm;
}
code {
font-size: 25pt;
font-family: monospace;
background-color: #401f3124;
color: #753657;
padding: 1.2mm;
line-height: 1;
border-radius: 2mm;
}
caption {
margin-bottom: 10px;
font-size: 20pt;
font-style: italic;
}

tbody tr:nth-child(odd) {
    background-color: #75365720;
}
.table>thead>tr>th, .table>tbody>tr>th, .table>tfoot>tr>th, .table>thead>tr>td, .table>tbody>tr>td, .table>tfoot>tr>td{
  border-spacing: 0;
  font-size: 40%;
  border-style: none;
  padding-top: 15px;
  padding-bottom: 15px;
  padding-right: 1em;
  padding-left: 1em;
  line-height: 1em;
}
table {
  margin: auto;
}
th {
  padding-left: 5mm;
  padding-right: 5mm;
}
.caption {
font-size: 20pt;
font-style: italic;
padding-top: 0;
}
.references {
font-size: 20px;
line-height: 90%;
}
/* Create three unequal columns that floats next to each other */
.column {
float: left;
padding: 0px;
}
.outer {
width: 46in;
height: 32in;
-webkit-column-count: 2; /* Chrome, Safari, Opera */
-moz-column-count: 2; /* Firefox */
column-count: 2;
-webkit-column-fill: auto;
-moz-column-fill: auto;
column-fill: auto;
-webkit-column-rule-width: 50%;
-moz-column-rule-width: 50%;
column-rule-width: 50%;
-webkit-column-rule-style: solid;
-moz-column-rule-style: solid;
column-rule-style: solid;
-webkit-column-rule-color: black;
-moz-column-rule-color: black;
column-rule-color: black;
-webkit-column-gap: 50%;
background-color: #ffffff;
font-family: Rasa;
color: #000000;
}
span.citation {
  color: #401f31;
  font-weight: bold;
}
a {
text-decoration: none;
color: #401f31;
}
#title {
font-size: 100pt;
text-align: left;
margin: 0;
line-height: 90%;
border-bottom: 0;
}
#author {
color: #753657;
margin: 0;
line-height: 90%;
font-size: 1.17em;
}
#affiliation {
padding-top: 1em;
color: #00000060;
font-style: italic;
font-size: 25px;
margin: 0;
}
sup {
color: #008080;
}
.affiliation sup {
font-size: 20px;
}
.author sup {
font-size: 30px;
}
.author_extra {
color: #401f31;
margin: 0;
line-height: 85%;
font-size: 35px;
}
.outer h1 {
text-align: center;
margin-top: 0.5in;
margin-bottom: 0.5in;
}
.outer h2 {
text-align: center;
}
.outer p {
color: #000000;
}
.outer ol {
text-align: left;
}
.main {
width: calc(46in / 2);
height: 32in;
position: absolute;
margin-left: calc(46in / 4);
background-color: #753657;
color: #FFFFFF90;
font-family: Rasa;
background-image: linear-gradient(#753657 50%, #401f31);
}
.main strong {
color: #FFFFFF;
}
img.main-img-left {
width: 20%;
left: 0.5in;
bottom: 0.2in;
position: absolute;
}
img.main-img-right {
width: 18%;
right: 0.5in;
bottom: 0.2in;
position: absolute;
}
.main p {
padding-top: 20%;
font-size: 170px;
text-align: left;
}
.fab {
color: #00000060;
font-size: 25px;
}
.twitter, i {
color: #00000060;
font-size: 35px;
text-decoration: none;
}
a.email {
text-decoration: none;
color: #00000060;
font-size: 35px;
}
.envelope {
color: #00000060;
font-size: 5px;
text-decoration: none;
}
.poster_wrap {
width: 46in;
height: 32in;
padding: 0cm;
background-color: #ffffff;
}
span > #tab:mytable {
  font-weight: bold;
}
.section {
  padding-left: 10mm;
  padding-right: 10mm;
}
.main p {
  padding-left: 30mm;
  padding-right: 30mm;
}
.main_pic {
  width: 50%;
  display: block;
  margin-left: auto;
  margin-right: auto;
}
.orcid img {
  width: 3%;
}
</style>
</head>
<body>


<div class="poster_wrap">
<div class="column outer">
<br>
<div class="title section">
<h1 id="title">Cost-Effectiveness of RSV Preventive Interventions in Mali</h1>
<br>
<h3 id="author" class="author">

Rachel S. Laufer, MPH<sup> 1, <a class="orcid" href="https://orcid.org/0000-0003-3142-9347"><img src="https://raw.githubusercontent.com/brentthorne/posterdown/master/images/orcid.jpg"></a></sup><br>

<a class='envelope'><i class="fas fa-envelope"></i></a> <a href="mailto:rlaufer@som.umaryland.edu" class="email">rlaufer@som.umaryland.edu</a> <br>
       </h3>

<h5 id="author_extra" class="author_extra">
 James D. Campbell, MD<sup>1</sup>
 Amanda J. Driscoll, PhD<sup>1</sup>
 Karen L. Kotloff, MD<sup>1</sup>
 Kathleen M. Neuzil, MD<sup>1</sup>
 Justin R. Ortiz, MD<sup>1, <a class="orcid" href="https://orcid.org/0000-0002-3138-5965"><img src="https://raw.githubusercontent.com/brentthorne/posterdown/master/images/orcid.jpg"></a></sup>
 Milagritos D. Tapia, MD<sup>1</sup>
 Meagan C. Fitzpatrick, PhD<sup>1, <a class="orcid" href="https://orcid.org/0000-0002-5248-2668"><img src="https://raw.githubusercontent.com/brentthorne/posterdown/master/images/orcid.jpg"></a></sup>
</h5>

<p id="affiliation" class="affiliation">
<sup>1</sup> Center for Vaccine Development and Global Health, Univeristy of Maryland School of Medicine
</p>

</div>
<div id="disclosures" class="section level3">
<h3>Disclosures</h3>
<p>The authors have nothing to disclose.</p>
</div>
<div id="introduction" class="section level1">
<h1>Introduction</h1>
<ul>
<li>Respiratory syncytial virus (RSV) is the leading cause of acute lower-respiratory tract infections in infants.</li>
<li>Developing countries have the most RSV associated infant morbidity and mortality. <span class="citation">(Shi et al. <a href="#ref-RN5">2017</a>)</span></li>
<li>The current monoclonal antibody, Palivizumab, is cost-prohibitive for low-resource settings.</li>
<li>New products for RSV prevention are in development. <span class="citation">(Web Page <a href="#ref-RN38">2019</a>)</span></li>
</ul>
<div id="objective" class="section level2">
<h2>Objective</h2>
<p>Evaluate the cost-effectiveness of current and novel RSV preventive interventions in Mali to inform policy recommendations for low-resource countries</p>
</div>
</div>
<div id="methods" class="section level1">
<h1>Methods</h1>
<p>Our model considers four scenarios:</p>
<ol style="list-style-type: decimal">
<li>No intervention</li>
<li>Monthly dose of Palivizumab (mAb)</li>
<li>Single dose of long-lasting MEDI8897 (llAb)</li>
<li>Infant mothers receive ResVax (mVax)</li>
</ol>
<ul>
<li>We simulated the epidemiological impact of each scenario using a monthly cohort model</li>
<li>We estimated associated health and economic costs</li>
<li>We evaluated cost-effectiveness using WHO standards</li>
</ul>
<p><br></p>
</div>
<div id="results" class="section level1">
<h1>Results</h1>
<p>Our analysis indicates that the long-lasting monoclonal antibody would have the largest health impact in terms of DALYs averted, Figure <a href="#fig:FrontiersDALYs">1</a>.</p>
<div class="figure" style="text-align: center"><span id="fig:FrontiersDALYs"></span>
<img src="Figures/FrontiersDALYs.jpeg" alt="Disability-adjusted life years (DALYs) averted as coverage increases for each intervention." width="80%" />
<p class="caption">
Figure 1: Disability-adjusted life years (DALYs) averted as coverage increases for each intervention.
</p>
</div>
<p>The mAb, llAb, and mVax would be considered <strong>very cost-effective</strong> at up to $15, $65, and $27 per dose respectively, Figure <a href="#fig:FrontiersThresholdCosts">2</a>.</p>
<div class="figure" style="text-align: center"><span id="fig:FrontiersThresholdCosts"></span>
<img src="Figures/FrontiersThresholdCosts.jpeg" alt="Incremental cost-effectiveness ratio (ICER) as cost per dose increases for each intervention. The red dashed line indicates the **very cost-effective** threshold, equal to the per capita GDP of Mali." width="80%" />
<p class="caption">
Figure 2: Incremental cost-effectiveness ratio (ICER) as cost per dose increases for each intervention. The red dashed line indicates the <strong>very cost-effective</strong> threshold, equal to the per capita GDP of Mali.
</p>
</div>
<p>If llAb were priced at less than ~$40 per dose upon market licensure then it might provide greater value for money than mVax, Figure <a href="#fig:HeadtoHead">3</a>.</p>
<div class="figure" style="text-align: center"><span id="fig:HeadtoHead"></span>
<img src="Figures/mVax_vs_llAb.jpeg" alt="Probability mVax has greater net health benefits than llAb at a given cost per dose for each intervention" width="80%" />
<p class="caption">
Figure 3: Probability mVax has greater net health benefits than llAb at a given cost per dose for each intervention
</p>
</div>
<div id="references" class="section level2 unnumbered">
<h2>References</h2>
<div id="refs" class="references">
<div id="ref-RN5">
<p>Shi, T., D. A. McAllister, K. L. O’Brien, E. A. F. Simoes, S. A. Madhi, B. D. Gessner, F. P. Polack, et al. 2017. “Global, Regional, and National Disease Burden Estimates of Acute Lower Respiratory Infections Due to Respiratory Syncytial Virus in Young Children in 2015: A Systematic Review and Modelling Study.” Journal Article. <em>Lancet</em> 390 (10098): 946–58. <a href="https://doi.org/10.1016/s0140-6736(17)30938-8">https://doi.org/10.1016/s0140-6736(17)30938-8</a>.</p>
</div>
<div id="ref-RN38">
<p>Web Page. 2019. <a href="https://path.org/resources/rsv-vaccine-and-mab-snapshot/">https://path.org/resources/rsv-vaccine-and-mab-snapshot/</a>.</p>
</div>
</div>
</div>
</div>

</div>
<div class="main">
<p>New Long-Lasting <strong>Monoclonal Antibody</strong> May Be <strong>Cost-Effective</strong> Investment to Protect Infants from <strong>RSV</strong> in Low-Resource Countries<br><br> <img src="https://www.medschool.umaryland.edu/media/SOM/Institutes/CVDGH/images/CVGGH_Globe_grey10.png" class="main_pic" /></p>
<img src="https://raw.githubusercontent.com/brentthorne/posterdown/master/images/qr-code-black.png" class="main-img-left" />
<img src="Figures/CVDGH_UMSOM_logo.png" class="main-img-right" />
</div>
</div>



</body>
</html>
